MTPA's oral therapy Radicava (edaravone) has shown decreased functional decline and improved survival in long-term ALS trials ...

Adults with SBMA have elevated levels of NfL and GFAP, two biomarkers for nerve damage, in their cerebrospinal fluid, a study ...

A compound normally associated with red blood cells may also play a game-changing antioxidant role in the brain, a study has ...

This year's ALS Nexus conference allowed the community to connect with each other, celebrate recent advances, and share hope ...

Scientists have created a lifelike model of Amyotrophic Lateral Sclerosis (ALS), a type of motor neuron disease, using cells ...

Many people will never know the last time they will do certain things in life. Even though he navigates sometimes trying days ...

Dublin, July 23, 2025 (GLOBE NEWSWIRE) -- The "Amyotrophic Lateral Sclerosis Market Report and Forecast 2025-2034" report has been added to ResearchAndMarkets.com's offering. The amyotrophic ...

• Key Amyotrophic Lateral Sclerosis Pipeline Therapies: ION363, FB418, SRK-015, RNS60, QRL-201, SAR443820, MN-166, VM202, VRG-50635, Zilucoplan, and others.

Familial amyotrophic lateral sclerosis (ALS) is an uncommon form of ALS that occurs due to an inherited gene. The disease causes motor neurons to die, which can lead to progressive muscle weakness.